Efficacy and safety of traditional Chinese medicine injections in the treatment of chronic obstructive pulmonary disease: A protocol for systematic review and network meta-analysis

Chronic obstructive pulmonary disease (COPD) is a widespread, heterogeneous disease characterized by chronic inflammation of the airway and the gradual blockage of air flow due to bronchial obstruction. At present, a large number of traditional Chinese medicine injections (TCMIs) has been applied in...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:Medicine (Baltimore) 2021-09, Vol.100 (38), p.e27324-e27324
Hauptverfasser: Sun, Zhongli, Zhao, Wei, Yang, Kun, Li, Xingying, Yu, Penglong
Format: Artikel
Sprache:eng
Schlagworte:
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
container_end_page e27324
container_issue 38
container_start_page e27324
container_title Medicine (Baltimore)
container_volume 100
creator Sun, Zhongli
Zhao, Wei
Yang, Kun
Li, Xingying
Yu, Penglong
description Chronic obstructive pulmonary disease (COPD) is a widespread, heterogeneous disease characterized by chronic inflammation of the airway and the gradual blockage of air flow due to bronchial obstruction. At present, a large number of traditional Chinese medicine injections (TCMIs) has been applied in the clinical treatment of COPD. However, there is insufficient evidence of evidence-based medicine of the interaction between them. Therefore, the purpose of this study is through the network meta-analysis to evaluate the efficacy and safety of the different TCMIs treatment of COPD, offering reference and evidence for clinical application. We will search 7 databases for randomized controlled trials of TCMI for the COPD, including PubMed, the Cochrane Library, EMbase, China National Knowledge Infrastructure, China Biological Medicine, Chinese Scientific Journals Database, and Wan-fang databases, from the date of the establishment of each database to October 31, 2021. The network meta-analysis will be implemented through Aggregate Data Drug Information System 1.16.8 and Stata 13.0 software. Pulmonary function included forced expiratory volume in 1 second (FEV1), forced vital capacity (FVC), and FEV1/FVC will be the primary outcomes, FEV1 as a percentage of the estimated value (FEV1%pred), maximal voluntary ventilation (MVV), MVV as a percentage of the estimated value (MVV%pred), 6 minutes walking distance, The St. George's Respiratory Questionnaire score, and safety/adverse event will be evaluated as secondary outcomes. Mean differences or odds ratios will be used for statistical analysis. We will ensure the reliability of the results through node-split model and heterogeneity analysis. In addition, methodological quality will be evaluated based on the Cochrane Collaboration's tool, and the quality of evidence will be evaluated according to the Grading of Recommendations Assessment, Development and Evaluation system. This study will provide reliable evidence for the clinical selection of TCMI in the treatment of COPD. The results of this study will evaluate the efficacy and safety of TCMI in the treatment of COPD, and provide decision-making references for future clinical and scientific research.
doi_str_mv 10.1097/MD.0000000000027324
format Article
fullrecord <record><control><sourceid>proquest_pubme</sourceid><recordid>TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_8462615</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>2576657455</sourcerecordid><originalsourceid>FETCH-LOGICAL-c3550-cac90ec48ce5425c665f617c43e3ade76942bb35ad50bed34b24088d1b9c3d3d3</originalsourceid><addsrcrecordid>eNpdUU1v1DAQtRCIbhd-ARLykUuK4494wwGp2paC1IoLnC3HmRC3SbzYzq72f_UHMtst5cM-eDR-7808PULelOysZLV-f3Nxxv4crgWXz8iiVKIqVF3J52SBXVXoWssTcprSLWOl0Fy-JCdCKlWXqlyQ-8uu8866PbVTS5PtIO9p6GiOtvXZh8kOdN37CRLQEVrvsKR-ugV3-ExY0twDwsHmEaZ84Lo-hsk7GpqU44zALdDNPIwoFve09Qlsgg_0nG5iyMGFgXYh0rRPGUabkRhh62H3sNEEeRfiHc7OtrC4zT759Iq86OyQ4PXjuyTfP11-W38urr9efVmfXxdOKMUKtFUzcHLlQEmuXFWpriq1kwKEbUFXteRNI5RtFWugFbLhkq1WbdnUTrR4l-TjUXczN2jeob9oB7OJfkQnJlhv_v2ZfG9-hK1ZyYpXmMSSvHsUiOHnDCmb0ScHw2AnCHMyXGlcSmMaCBVHqIshpQjd05iSmUPe5ubC_J83st7-veET53fACJBHwC4MGWK6G-YdRNODHXL_oKd0zQvOOM5A-wV2KiZ-AV75u_4</addsrcrecordid><sourcetype>Open Access Repository</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2576657455</pqid></control><display><type>article</type><title>Efficacy and safety of traditional Chinese medicine injections in the treatment of chronic obstructive pulmonary disease: A protocol for systematic review and network meta-analysis</title><source>MEDLINE</source><source>DOAJ Directory of Open Access Journals</source><source>Wolters Kluwer Open Health</source><source>IngentaConnect Free/Open Access Journals</source><source>EZB-FREE-00999 freely available EZB journals</source><source>PubMed Central</source><source>Alma/SFX Local Collection</source><creator>Sun, Zhongli ; Zhao, Wei ; Yang, Kun ; Li, Xingying ; Yu, Penglong</creator><creatorcontrib>Sun, Zhongli ; Zhao, Wei ; Yang, Kun ; Li, Xingying ; Yu, Penglong</creatorcontrib><description>Chronic obstructive pulmonary disease (COPD) is a widespread, heterogeneous disease characterized by chronic inflammation of the airway and the gradual blockage of air flow due to bronchial obstruction. At present, a large number of traditional Chinese medicine injections (TCMIs) has been applied in the clinical treatment of COPD. However, there is insufficient evidence of evidence-based medicine of the interaction between them. Therefore, the purpose of this study is through the network meta-analysis to evaluate the efficacy and safety of the different TCMIs treatment of COPD, offering reference and evidence for clinical application. We will search 7 databases for randomized controlled trials of TCMI for the COPD, including PubMed, the Cochrane Library, EMbase, China National Knowledge Infrastructure, China Biological Medicine, Chinese Scientific Journals Database, and Wan-fang databases, from the date of the establishment of each database to October 31, 2021. The network meta-analysis will be implemented through Aggregate Data Drug Information System 1.16.8 and Stata 13.0 software. Pulmonary function included forced expiratory volume in 1 second (FEV1), forced vital capacity (FVC), and FEV1/FVC will be the primary outcomes, FEV1 as a percentage of the estimated value (FEV1%pred), maximal voluntary ventilation (MVV), MVV as a percentage of the estimated value (MVV%pred), 6 minutes walking distance, The St. George's Respiratory Questionnaire score, and safety/adverse event will be evaluated as secondary outcomes. Mean differences or odds ratios will be used for statistical analysis. We will ensure the reliability of the results through node-split model and heterogeneity analysis. In addition, methodological quality will be evaluated based on the Cochrane Collaboration's tool, and the quality of evidence will be evaluated according to the Grading of Recommendations Assessment, Development and Evaluation system. This study will provide reliable evidence for the clinical selection of TCMI in the treatment of COPD. The results of this study will evaluate the efficacy and safety of TCMI in the treatment of COPD, and provide decision-making references for future clinical and scientific research.</description><identifier>ISSN: 0025-7974</identifier><identifier>EISSN: 1536-5964</identifier><identifier>DOI: 10.1097/MD.0000000000027324</identifier><identifier>PMID: 34559151</identifier><language>eng</language><publisher>United States: Lippincott Williams &amp; Wilkins</publisher><subject>Drugs, Chinese Herbal - therapeutic use ; Humans ; Injections ; Medicine, Chinese Traditional ; Meta-Analysis as Topic ; Pulmonary Disease, Chronic Obstructive - drug therapy ; Study Protocol Systematic Review ; Systematic Reviews as Topic ; Treatment Outcome</subject><ispartof>Medicine (Baltimore), 2021-09, Vol.100 (38), p.e27324-e27324</ispartof><rights>Lippincott Williams &amp; Wilkins</rights><rights>Copyright © 2021 the Author(s). Published by Wolters Kluwer Health, Inc.</rights><rights>Copyright © 2021 the Author(s). Published by Wolters Kluwer Health, Inc. 2021</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><cites>FETCH-LOGICAL-c3550-cac90ec48ce5425c665f617c43e3ade76942bb35ad50bed34b24088d1b9c3d3d3</cites><orcidid>0000-0001-7659-8991</orcidid></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC8462615/pdf/$$EPDF$$P50$$Gpubmedcentral$$Hfree_for_read</linktopdf><linktohtml>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC8462615/$$EHTML$$P50$$Gpubmedcentral$$Hfree_for_read</linktohtml><link.rule.ids>230,314,723,776,780,860,881,27903,27904,53770,53772</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/34559151$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Sun, Zhongli</creatorcontrib><creatorcontrib>Zhao, Wei</creatorcontrib><creatorcontrib>Yang, Kun</creatorcontrib><creatorcontrib>Li, Xingying</creatorcontrib><creatorcontrib>Yu, Penglong</creatorcontrib><title>Efficacy and safety of traditional Chinese medicine injections in the treatment of chronic obstructive pulmonary disease: A protocol for systematic review and network meta-analysis</title><title>Medicine (Baltimore)</title><addtitle>Medicine (Baltimore)</addtitle><description>Chronic obstructive pulmonary disease (COPD) is a widespread, heterogeneous disease characterized by chronic inflammation of the airway and the gradual blockage of air flow due to bronchial obstruction. At present, a large number of traditional Chinese medicine injections (TCMIs) has been applied in the clinical treatment of COPD. However, there is insufficient evidence of evidence-based medicine of the interaction between them. Therefore, the purpose of this study is through the network meta-analysis to evaluate the efficacy and safety of the different TCMIs treatment of COPD, offering reference and evidence for clinical application. We will search 7 databases for randomized controlled trials of TCMI for the COPD, including PubMed, the Cochrane Library, EMbase, China National Knowledge Infrastructure, China Biological Medicine, Chinese Scientific Journals Database, and Wan-fang databases, from the date of the establishment of each database to October 31, 2021. The network meta-analysis will be implemented through Aggregate Data Drug Information System 1.16.8 and Stata 13.0 software. Pulmonary function included forced expiratory volume in 1 second (FEV1), forced vital capacity (FVC), and FEV1/FVC will be the primary outcomes, FEV1 as a percentage of the estimated value (FEV1%pred), maximal voluntary ventilation (MVV), MVV as a percentage of the estimated value (MVV%pred), 6 minutes walking distance, The St. George's Respiratory Questionnaire score, and safety/adverse event will be evaluated as secondary outcomes. Mean differences or odds ratios will be used for statistical analysis. We will ensure the reliability of the results through node-split model and heterogeneity analysis. In addition, methodological quality will be evaluated based on the Cochrane Collaboration's tool, and the quality of evidence will be evaluated according to the Grading of Recommendations Assessment, Development and Evaluation system. This study will provide reliable evidence for the clinical selection of TCMI in the treatment of COPD. The results of this study will evaluate the efficacy and safety of TCMI in the treatment of COPD, and provide decision-making references for future clinical and scientific research.</description><subject>Drugs, Chinese Herbal - therapeutic use</subject><subject>Humans</subject><subject>Injections</subject><subject>Medicine, Chinese Traditional</subject><subject>Meta-Analysis as Topic</subject><subject>Pulmonary Disease, Chronic Obstructive - drug therapy</subject><subject>Study Protocol Systematic Review</subject><subject>Systematic Reviews as Topic</subject><subject>Treatment Outcome</subject><issn>0025-7974</issn><issn>1536-5964</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2021</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNpdUU1v1DAQtRCIbhd-ARLykUuK4494wwGp2paC1IoLnC3HmRC3SbzYzq72f_UHMtst5cM-eDR-7808PULelOysZLV-f3Nxxv4crgWXz8iiVKIqVF3J52SBXVXoWssTcprSLWOl0Fy-JCdCKlWXqlyQ-8uu8866PbVTS5PtIO9p6GiOtvXZh8kOdN37CRLQEVrvsKR-ugV3-ExY0twDwsHmEaZ84Lo-hsk7GpqU44zALdDNPIwoFve09Qlsgg_0nG5iyMGFgXYh0rRPGUabkRhh62H3sNEEeRfiHc7OtrC4zT759Iq86OyQ4PXjuyTfP11-W38urr9efVmfXxdOKMUKtFUzcHLlQEmuXFWpriq1kwKEbUFXteRNI5RtFWugFbLhkq1WbdnUTrR4l-TjUXczN2jeob9oB7OJfkQnJlhv_v2ZfG9-hK1ZyYpXmMSSvHsUiOHnDCmb0ScHw2AnCHMyXGlcSmMaCBVHqIshpQjd05iSmUPe5ubC_J83st7-veET53fACJBHwC4MGWK6G-YdRNODHXL_oKd0zQvOOM5A-wV2KiZ-AV75u_4</recordid><startdate>20210924</startdate><enddate>20210924</enddate><creator>Sun, Zhongli</creator><creator>Zhao, Wei</creator><creator>Yang, Kun</creator><creator>Li, Xingying</creator><creator>Yu, Penglong</creator><general>Lippincott Williams &amp; Wilkins</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope><scope>5PM</scope><orcidid>https://orcid.org/0000-0001-7659-8991</orcidid></search><sort><creationdate>20210924</creationdate><title>Efficacy and safety of traditional Chinese medicine injections in the treatment of chronic obstructive pulmonary disease: A protocol for systematic review and network meta-analysis</title><author>Sun, Zhongli ; Zhao, Wei ; Yang, Kun ; Li, Xingying ; Yu, Penglong</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c3550-cac90ec48ce5425c665f617c43e3ade76942bb35ad50bed34b24088d1b9c3d3d3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2021</creationdate><topic>Drugs, Chinese Herbal - therapeutic use</topic><topic>Humans</topic><topic>Injections</topic><topic>Medicine, Chinese Traditional</topic><topic>Meta-Analysis as Topic</topic><topic>Pulmonary Disease, Chronic Obstructive - drug therapy</topic><topic>Study Protocol Systematic Review</topic><topic>Systematic Reviews as Topic</topic><topic>Treatment Outcome</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Sun, Zhongli</creatorcontrib><creatorcontrib>Zhao, Wei</creatorcontrib><creatorcontrib>Yang, Kun</creatorcontrib><creatorcontrib>Li, Xingying</creatorcontrib><creatorcontrib>Yu, Penglong</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><collection>PubMed Central (Full Participant titles)</collection><jtitle>Medicine (Baltimore)</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Sun, Zhongli</au><au>Zhao, Wei</au><au>Yang, Kun</au><au>Li, Xingying</au><au>Yu, Penglong</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Efficacy and safety of traditional Chinese medicine injections in the treatment of chronic obstructive pulmonary disease: A protocol for systematic review and network meta-analysis</atitle><jtitle>Medicine (Baltimore)</jtitle><addtitle>Medicine (Baltimore)</addtitle><date>2021-09-24</date><risdate>2021</risdate><volume>100</volume><issue>38</issue><spage>e27324</spage><epage>e27324</epage><pages>e27324-e27324</pages><issn>0025-7974</issn><eissn>1536-5964</eissn><abstract>Chronic obstructive pulmonary disease (COPD) is a widespread, heterogeneous disease characterized by chronic inflammation of the airway and the gradual blockage of air flow due to bronchial obstruction. At present, a large number of traditional Chinese medicine injections (TCMIs) has been applied in the clinical treatment of COPD. However, there is insufficient evidence of evidence-based medicine of the interaction between them. Therefore, the purpose of this study is through the network meta-analysis to evaluate the efficacy and safety of the different TCMIs treatment of COPD, offering reference and evidence for clinical application. We will search 7 databases for randomized controlled trials of TCMI for the COPD, including PubMed, the Cochrane Library, EMbase, China National Knowledge Infrastructure, China Biological Medicine, Chinese Scientific Journals Database, and Wan-fang databases, from the date of the establishment of each database to October 31, 2021. The network meta-analysis will be implemented through Aggregate Data Drug Information System 1.16.8 and Stata 13.0 software. Pulmonary function included forced expiratory volume in 1 second (FEV1), forced vital capacity (FVC), and FEV1/FVC will be the primary outcomes, FEV1 as a percentage of the estimated value (FEV1%pred), maximal voluntary ventilation (MVV), MVV as a percentage of the estimated value (MVV%pred), 6 minutes walking distance, The St. George's Respiratory Questionnaire score, and safety/adverse event will be evaluated as secondary outcomes. Mean differences or odds ratios will be used for statistical analysis. We will ensure the reliability of the results through node-split model and heterogeneity analysis. In addition, methodological quality will be evaluated based on the Cochrane Collaboration's tool, and the quality of evidence will be evaluated according to the Grading of Recommendations Assessment, Development and Evaluation system. This study will provide reliable evidence for the clinical selection of TCMI in the treatment of COPD. The results of this study will evaluate the efficacy and safety of TCMI in the treatment of COPD, and provide decision-making references for future clinical and scientific research.</abstract><cop>United States</cop><pub>Lippincott Williams &amp; Wilkins</pub><pmid>34559151</pmid><doi>10.1097/MD.0000000000027324</doi><orcidid>https://orcid.org/0000-0001-7659-8991</orcidid><oa>free_for_read</oa></addata></record>
fulltext fulltext
identifier ISSN: 0025-7974
ispartof Medicine (Baltimore), 2021-09, Vol.100 (38), p.e27324-e27324
issn 0025-7974
1536-5964
language eng
recordid cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_8462615
source MEDLINE; DOAJ Directory of Open Access Journals; Wolters Kluwer Open Health; IngentaConnect Free/Open Access Journals; EZB-FREE-00999 freely available EZB journals; PubMed Central; Alma/SFX Local Collection
subjects Drugs, Chinese Herbal - therapeutic use
Humans
Injections
Medicine, Chinese Traditional
Meta-Analysis as Topic
Pulmonary Disease, Chronic Obstructive - drug therapy
Study Protocol Systematic Review
Systematic Reviews as Topic
Treatment Outcome
title Efficacy and safety of traditional Chinese medicine injections in the treatment of chronic obstructive pulmonary disease: A protocol for systematic review and network meta-analysis
url https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-21T11%3A43%3A41IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_pubme&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Efficacy%20and%20safety%20of%20traditional%20Chinese%20medicine%20injections%20in%20the%20treatment%20of%20chronic%20obstructive%20pulmonary%20disease:%20A%20protocol%20for%20systematic%20review%20and%20network%20meta-analysis&rft.jtitle=Medicine%20(Baltimore)&rft.au=Sun,%20Zhongli&rft.date=2021-09-24&rft.volume=100&rft.issue=38&rft.spage=e27324&rft.epage=e27324&rft.pages=e27324-e27324&rft.issn=0025-7974&rft.eissn=1536-5964&rft_id=info:doi/10.1097/MD.0000000000027324&rft_dat=%3Cproquest_pubme%3E2576657455%3C/proquest_pubme%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=2576657455&rft_id=info:pmid/34559151&rfr_iscdi=true